share_log

Noble Capital Markets Initiates Coverage On Cadrenal Therapeutics With Outperform Rating, Announces Price Target of $4

Benzinga ·  Dec 18, 2023 09:09

Noble Capital Markets analyst Robert LeBoyer initiates coverage on Cadrenal Therapeutics (NASDAQ:CVKD) with a Outperform rating and announces Price Target of $4.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment